Onconova Therapeutics, Inc. (ONTX)
(Delayed Data from NSDQ)
$4.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Onconova's Cancer Study Fails to Meet Endpoint, Shares Down
by Zacks Equity Research
Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.
Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.
Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
by Zacks Equity Research
Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.
Will Onconova Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Onconova Therapeutics.
Onconova (ONTX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
Onconova Therapeutics, Inc. (ONTX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Onconova Therapeutics, Inc. (ONTX).
US Dollar Flexes Muscles Against Other Currencies: 5 Winners
by Tirthankar Chakraborty
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
Coronavirus to Hit Apple Sales: Invest in Domestic Producers
by Tirthankar Chakraborty
With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.
Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Onconova Therapeutics (ONTX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for April 05, 2017
by Zacks Equity Research
Company News for April 05, 2017